Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
10.7774/cevr.2022.11.1.116
- Author:
Juandy JO
1
;
Astia SANJAYA
;
Reinhard PINONTOAN
;
Maroloan ARUAN
;
Rury Mega WAHYUNI
;
Venansi VIKTARIA
Author Information
1. Department of Biology, Universitas Pelita Harapan, Tangerang, Indonesia
- Publication Type:Brief Communication
- From:Clinical and Experimental Vaccine Research
2022;11(1):116-120
- CountryRepublic of Korea
- Language:English
-
Abstract:
The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.
